- $25.54bn
- $27.87bn
- $9.68bn
- 87
- 82
- 92
- 99
Annual balance sheet for Biogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2,610 | 3,803 | 4,893 | 1,050 | 2,375 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2,327 | 1,962 | 2,136 | 2,100 | 1,869 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 6,887 | 7,857 | 9,791 | 6,859 | 7,457 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,845 | 3,792 | 3,703 | 3,730 | 3,538 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 24,619 | 23,877 | 24,554 | 26,845 | 28,049 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3,742 | 4,298 | 3,273 | 3,434 | 5,529 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 13,919 | 12,981 | 11,156 | 12,045 | 11,333 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 10,700 | 10,896 | 13,398 | 14,799 | 16,716 |
| Total Liabilities & Shareholders' Equity | 24,619 | 23,877 | 24,554 | 26,845 | 28,049 |
| Total Common Shares Outstanding |